Figure 5
From: Pitavastatin in cardiometabolic disease: therapeutic profile
Pitavastatin presents significant reductions in hemoglobin A1c levels that continue over time. Pitavastatin is associated with significant reductions in hemoglobin A1c (HbA1c) levels that continue to decrease over time (LIVES study). Values are mean ± standard deviation. ANOVA, analysis of variance. Adapted from [46].